MyoKardia Inc. | Mutual Funds
Mutual Funds that own MyoKardia Inc.
Fidelity Growth Company Fund
1,445,478
3.6%
63,113
0.18%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,152,901
2.87%
0
0.77%
07/31/2018
Vanguard Total Stock Market Index Fund
851,509
2.12%
12,144
0.01%
07/31/2018
iShares Russell 2000 ETF
638,290
1.59%
-342
0.08%
09/06/2018
iShares Nasdaq Biotechnology ETF
458,913
1.13%
-6,006
0.28%
09/06/2018
Vanguard Extended Market Index Fund
436,994
1.09%
0
0.04%
07/31/2018
Vanguard Small Cap Index Fund
425,203
1.06%
6,963
0.03%
07/31/2018
Fidelity Series Growth Company Fund
406,400
1.01%
19,400
0.19%
07/31/2018
Fidelity Advisor Biotechnology Fund
390,446
0.97%
-263,879
0.83%
07/31/2018
Fidelity Select Health Care Portfolio
320,018
0.8%
11,100
0.26%
07/31/2018
| Address |
333 Allerton Avenue
San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.myokardia.com |
| Updated |
07/08/2019 |
| MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. |
